Back to Search
Start Over
Five-year outcome of self-expanding covered stents for superficial femoral artery occlusive disease and an analysis of factors predicting failure
- Source :
- Journal of Endovascular Therapy, 22(6), 855. International Society of Endovascular Specialists, Journal of Endovascular Therapy, 22(6), 855-861. SAGE Publications Inc.
- Publication Year :
- 2015
-
Abstract
- Purpose: To investigate the 5-year outcome of patients treated with self-expanding covered stents for superficial femoral artery (SFA) occlusive disease and identify parameters that could predict loss of primary patency. Methods: In a dual-center study, 315 consecutive patients (mean age 69.0 +/- 10.1 years; 232 men) treated for SFA occlusive disease in 334 limbs with Viabahn self-expanding covered stents between 2001 and 2014 were retrospectively analyzed. Mean lesion length was 11.7 +/- 8.8 cm, and half of the lesions were classified as TASC II C/D. Five-year patency rates were calculated, and Cox regression analyses were performed to assess potential factors affecting patency. Results: All-cause mortality at 5 years was 14.1%. Primary patency rates at 1, 3, and 5 years were 72.2%, 51.8%, and 47.6%, respectively, with secondary patency rates of 86.2%, 78.7%, and 77.5%. Parameters predicting loss of primary patency in a univariate analysis were covered stent diameter (rho=0.001), the number of covered stents per lesion (rho=0.015), and TASC II D classification (rho=0.007). Covered stent diameter was the only parameter predicting loss of primary patency in the multivariate regression analysis (rho=0.001), with 7-mm covered stents having superior performance. Conclusion: Five-year patency rates of self-expanding covered stents inserted for SFA occlusive disease are within an acceptable range. Covered stent diameter is the most relevant factor in predicting loss of primary patency, and thus, an adequate diameter of the distal landing site seems to be among the most important factors in the decision-making process. In smaller vessels, one should not use covered stents but venous conduits, as oversizing may be detrimental.
- Subjects :
- Nitinol stent
Male
Time Factors
medicine.medical_treatment
Superficial femoral artery
Occlusive disease
POPLITEAL BYPASS
Covered stent
NITINOL STENTS
Restenosis
CRITICAL LIMB ISCHEMIA
Treatment Failure
BARE-METAL STENTS
Outcome
Stenosis
Medicine(all)
Patency
Endovascular Procedures
RANDOMIZED CONTROLLED-TRIAL
Prognosis
Femoral Artery
Multicenter Study
Treatment Outcome
Female
Stents
Radiology
medicine.symptom
Cardiology and Cardiovascular Medicine
medicine.medical_specialty
Arterial Occlusive Diseases
Prosthesis Design
Stent diameter
Angioplasty
medicine
Journal Article
Humans
Radiology, Nuclear Medicine and imaging
Stent-graft
ANGIOPLASTY
Aged
Retrospective Studies
LESIONS
business.industry
GRAFT
Heparin bonding
Critical limb ischemia
medicine.disease
Surgery
RESTENOSIS
business
TASC-II
Subjects
Details
- Language :
- English
- ISSN :
- 15266028
- Database :
- OpenAIRE
- Journal :
- Journal of Endovascular Therapy, 22(6), 855. International Society of Endovascular Specialists, Journal of Endovascular Therapy, 22(6), 855-861. SAGE Publications Inc.
- Accession number :
- edsair.doi.dedup.....8f6a11b3140a799efeb739e88723ee67